The adjuvant chemotherapy of breast cancer
Semiglazov, V.F.; Golubeva, O.M.; Bavli, I.L.; Ivanova, O.A.; Topuzov, E.E.
Voprosy Onkologii 38(10): 1187-1194
1992
ISSN/ISBN: 0507-3758 PMID: 1343144 Document Number: 402344
A clinical trial undertaken at Surgical Department No. I of the Institute included the data on 569 cases of stage I-III breast cancer treated in 1985-1989. Adjuvant CMF or TMF chemotherapy failed to improved 5-year survival (chemotherapy 2--285.2%, no chemotherapy--84.8%) in patients with stage I-IIa (TO-2NOMO) disease. Adjuvant treatment with adrioblastin proved superior over CMF and TMF in terms of 5-year overall survival in patients with stage III (T3NO-IMO; TO-3N2MO) cancer (71.0 and 55.0%, respectively).